PLx Pharma Winddown Corp.

2017 Q1 Form 10-Q Financial Statement

#000114420417020705 Filed on April 17, 2017

View on sec.gov

Income Statement

Concept 2017 Q1 2016 Q4 2016 Q1

Balance Sheet

Concept 2017 Q1 2016 Q4 2016 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $12.41M $60.00K $27.15M
YoY Change -54.29% -99.81% 13.13%
Cash & Equivalents $425.8K $59.34K $4.170M
Short-Term Investments $22.98M
Other Short-Term Assets $80.00K $0.00 $110.0K
YoY Change -27.27% -100.0% -15.38%
Inventory $116.7K
Prepaid Expenses $83.02K $4.652K
Receivables $10.00K
Other Receivables $0.00
Total Short-Term Assets $12.53M $189.9K $27.26M
YoY Change -54.02% -99.41% 12.97%
LONG-TERM ASSETS
Property, Plant & Equipment $426.6K
YoY Change
Goodwill
YoY Change
Intangibles $0.00
YoY Change
Long-Term Investments
YoY Change
Other Assets $2.057M $56.63K $90.00K
YoY Change 2185.14% 14.67% 80.0%
Total Long-Term Assets $2.057M $426.6K $90.00K
YoY Change 2185.14% 763.89% 80.0%
TOTAL ASSETS
Total Short-Term Assets $12.53M $189.9K $27.26M
Total Long-Term Assets $2.057M $426.6K $90.00K
Total Assets $14.59M $616.5K $27.35M
YoY Change -46.65% -98.1% 13.11%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $60.00K $860.0K $40.00K
YoY Change 50.0% 2766.67% -33.33%
Accrued Expenses $400.0K $100.0K $830.0K
YoY Change -51.81% -93.67% 29.69%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $1.780M $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $460.0K $2.736M $870.0K
YoY Change -47.13% 69.93% 24.29%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00
YoY Change
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities $0.00 $0.00 $0.00
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities $460.0K $2.736M $870.0K
Total Long-Term Liabilities $0.00 $0.00 $0.00
Total Liabilities $462.1K $2.936M $870.0K
YoY Change -46.88% 82.77% 24.29%
SHAREHOLDERS EQUITY
Retained Earnings -$63.91M -$51.99M
YoY Change 26.6%
Common Stock $78.04M $49.67M
YoY Change -30.89%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $14.13M -$2.319M $26.48M
YoY Change
Total Liabilities & Shareholders Equity $14.59M $616.5K $27.35M
YoY Change -46.65% -98.1% 13.11%

Cashflow Statement

Concept 2017 Q1 2016 Q4 2016 Q1

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2017Q1 dei Document Type
DocumentType
10-Q
CY2017Q1 dei Amendment Flag
AmendmentFlag
false
CY2017Q1 dei Document Period End Date
DocumentPeriodEndDate
2017-03-31
CY2017Q1 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2017
CY2017Q1 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q1
CY2017Q1 dei Entity Registrant Name
EntityRegistrantName
Dipexium Pharmaceuticals, Inc.
CY2017Q1 dei Entity Central Index Key
EntityCentralIndexKey
0001497504
CY2017Q1 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2017Q1 dei Entity Filer Category
EntityFilerCategory
Smaller Reporting Company
CY2017Q1 dei Trading Symbol
TradingSymbol
DPRX
CY2017Q2 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
11230511 shares
CY2017Q1 us-gaap Cash
Cash
12414004 USD
CY2016Q4 us-gaap Cash
Cash
16675228 USD
CY2017Q1 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
83018 USD
CY2016Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
359015 USD
CY2017Q1 us-gaap Assets Current
AssetsCurrent
12533844 USD
CY2016Q4 us-gaap Assets Current
AssetsCurrent
17034243 USD
CY2017Q1 us-gaap Deposit Assets
DepositAssets
56630 USD
CY2016Q4 us-gaap Deposit Assets
DepositAssets
56630 USD
CY2016Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-5830874 USD
CY2017Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-63912449 USD
CY2016Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-62382584 USD
CY2017Q1 us-gaap Stockholders Equity
StockholdersEquity
14128338 USD
CY2016Q4 us-gaap Stockholders Equity
StockholdersEquity
14968980 USD
CY2017Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
14590474 USD
CY2016Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
17090873 USD
CY2017Q1 us-gaap Net Income Loss
NetIncomeLoss
-1529865 USD
CY2016Q1 us-gaap Net Income Loss
NetIncomeLoss
-5816632 USD
CY2017Q1 us-gaap Share Based Compensation
ShareBasedCompensation
689223 USD
CY2017Q1 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
2056630 USD
CY2016Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
56630 USD
CY2017Q1 us-gaap Assets
Assets
14590474 USD
CY2016Q4 us-gaap Assets
Assets
17090873 USD
CY2017Q1 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
462136 USD
CY2016Q4 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
2121893 USD
CY2017Q1 us-gaap Liabilities
Liabilities
462136 USD
CY2016Q4 us-gaap Liabilities
Liabilities
2121893 USD
CY2017Q1 us-gaap Common Stock Value
CommonStockValue
11130 USD
CY2016Q4 us-gaap Common Stock Value
CommonStockValue
11116 USD
CY2017Q1 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
78029657 USD
CY2016Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
77340448 USD
CY2016Q1 us-gaap Share Based Compensation
ShareBasedCompensation
1353093 USD
CY2017Q1 us-gaap Issuance Of Stock And Warrants For Services Or Claims
IssuanceOfStockAndWarrantsForServicesOrClaims
0 USD
CY2016Q1 us-gaap Issuance Of Stock And Warrants For Services Or Claims
IssuanceOfStockAndWarrantsForServicesOrClaims
145020 USD
CY2016Q1 dprx Amortization Of Interest Income
AmortizationOfInterestIncome
14135 USD
CY2017Q1 dprx Amortization Of Interest Income
AmortizationOfInterestIncome
0 USD
CY2017Q1 us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
-275997 USD
CY2016Q1 us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
-38175 USD
CY2017Q1 us-gaap Increase Decrease In Security Deposits
IncreaseDecreaseInSecurityDeposits
0 USD
CY2016Q1 us-gaap Increase Decrease In Security Deposits
IncreaseDecreaseInSecurityDeposits
-43532 USD
CY2016Q1 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-737160 USD
CY2017Q1 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-1659757 USD
CY2016Q1 us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-5075171 USD
CY2017Q1 us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-2261224 USD
CY2016Q1 us-gaap Proceeds From Sale Of Short Term Investments
ProceedsFromSaleOfShortTermInvestments
8000000 USD
CY2017Q1 us-gaap Proceeds From Sale Of Short Term Investments
ProceedsFromSaleOfShortTermInvestments
0 USD
CY2016Q1 us-gaap Payments To Acquire Short Term Investments
PaymentsToAcquireShortTermInvestments
3990107 USD
CY2017Q1 us-gaap Payments To Acquire Short Term Investments
PaymentsToAcquireShortTermInvestments
0 USD
CY2017Q1 us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
-2000000 USD
CY2016Q1 us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
4009893 USD
CY2017Q1 us-gaap Net Cash Provided By Used In Continuing Operations
NetCashProvidedByUsedInContinuingOperations
-4261224 USD
CY2016Q1 us-gaap Net Cash Provided By Used In Continuing Operations
NetCashProvidedByUsedInContinuingOperations
-1065278 USD
CY2016Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
16675228 USD
CY2015Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
5234953 USD
CY2017Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
12414004 USD
CY2017Q1 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
689223 USD
CY2017Q1 us-gaap Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
14688 USD
CY2016Q1 us-gaap Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
3583667 USD
CY2017Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1552329 USD
CY2016Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2247207 USD
CY2017Q1 us-gaap Operating Expenses
OperatingExpenses
1567017 USD
CY2016Q1 us-gaap Operating Expenses
OperatingExpenses
5830874 USD
CY2017Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-1567017 USD
CY2015Q2 us-gaap Proceeds From Issuance Initial Public Offering
ProceedsFromIssuanceInitialPublicOffering
19700000 USD
CY2017Q1 dprx Minimum Cash Balance To Be Maintained
MinimumCashBalanceToBeMaintained
12000000 USD
CY2017Q1 dprx Expected Percentage Own By Parent Company On Common Share Outstanding
ExpectedPercentageOwnByParentCompanyOnCommonShareOutstanding
0.2325 pure
CY2017Q1 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
37152 USD
CY2016Q1 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
14242 USD
CY2017Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.14
CY2016Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.56
CY2017Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
11123991 shares
CY2016Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
10315726 shares
CY2017Q1 us-gaap Revenues
Revenues
0 USD
CY2016Q1 us-gaap Revenues
Revenues
0 USD
CY2017Q1 dprx Termination Fee Payable
TerminationFeePayable
700000 USD
CY2017Q1 us-gaap Cash Cash Equivalents And Short Term Investments
CashCashEquivalentsAndShortTermInvestments
12400000 USD
CY2014Q1 us-gaap Proceeds From Issuance Initial Public Offering
ProceedsFromIssuanceInitialPublicOffering
34500000 USD
CY2017Q1 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
17463 USD
CY2016Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
579207 USD
CY2017Q1 dprx Accrued Research And Development Costs Current
AccruedResearchAndDevelopmentCostsCurrent
283123 USD
CY2016Q4 dprx Accrued Research And Development Costs Current
AccruedResearchAndDevelopmentCostsCurrent
460219 USD
CY2017Q1 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
101455 USD
CY2016Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
1040184 USD
CY2017Q1 dprx Other Accounts Payable And Accrued Expenses Current
OtherAccountsPayableAndAccruedExpensesCurrent
60095 USD
CY2016Q4 dprx Other Accounts Payable And Accrued Expenses Current
OtherAccountsPayableAndAccruedExpensesCurrent
42283 USD
CY2013Q4 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
2141169 shares
CY2017Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
7824 shares
CY2017Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
688332 shares
CY2017Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
1.80
CY2017Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Award Vesting Period1
ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
P24M
CY2017Q1 dprx Share Based Compensation To Vendors Research And Development Costs
ShareBasedCompensationToVendorsResearchAndDevelopmentCosts
0 USD
CY2016Q1 dprx Share Based Compensation To Vendors Research And Development Costs
ShareBasedCompensationToVendorsResearchAndDevelopmentCosts
145020 USD
CY2016Q4 us-gaap Operating Leases Future Minimum Payments Due Current
OperatingLeasesFutureMinimumPaymentsDueCurrent
174438 USD
CY2016Q4 us-gaap Operating Leases Future Minimum Payments Due In Two Years
OperatingLeasesFutureMinimumPaymentsDueInTwoYears
238004 USD
CY2016Q4 us-gaap Operating Leases Future Minimum Payments Due In Three Years
OperatingLeasesFutureMinimumPaymentsDueInThreeYears
244658 USD
CY2016Q4 us-gaap Operating Leases Future Minimum Payments Due In Four Years
OperatingLeasesFutureMinimumPaymentsDueInFourYears
251522 USD
CY2016Q4 us-gaap Operating Leases Future Minimum Payments Due In Five Years
OperatingLeasesFutureMinimumPaymentsDueInFiveYears
150347 USD
CY2016Q4 us-gaap Operating Leases Future Minimum Payments Due
OperatingLeasesFutureMinimumPaymentsDue
1058969 USD
CY2017Q1 us-gaap Interest Receivable Current
InterestReceivableCurrent
36822 USD
CY2017Q1 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
USD
CY2016Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
USD
CY2017Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2016Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2016Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
30000000 shares
CY2017Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
30000000 shares
CY2017Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
11129747 shares
CY2017Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
11129747 shares
CY2016Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
11115747 shares
CY2016Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
11115747 shares
CY2017Q1 us-gaap Use Of Estimates
UseOfEstimates
<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <b><u><font style="FONT-SIZE: 10pt">Use of Estimates</font></u></b></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. Actual results could differ from those estimates.</font></div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>
CY2017Q1 us-gaap Short Term Investments
ShortTermInvestments
0 USD
CY2016Q4 us-gaap Short Term Investments
ShortTermInvestments
0 USD
CY2017Q1 us-gaap Investment Income Interest
InvestmentIncomeInterest
36822 USD
CY2016Q1 us-gaap Investment Income Interest
InvestmentIncomeInterest
0 USD
CY2017Q1 us-gaap Loans Receivable Basis Spread On Variable Rate
LoansReceivableBasisSpreadOnVariableRate
0.08 pure
CY2017Q1 dprx Loan Receivable Maturity Date Description
LoanReceivableMaturityDateDescription
(a) October 15, 2017, or (b) the date that is two hundred seventy (270) days following the termination of the Merger Agreement, subject to acceleration in the event that (i) the Merger Agreement is terminated by Dipexium if PLx has breached any of its representations, warranties, covenants or agreements contained in the Merger Agreement such that the conditions to the closing of the Proposed Merger would not be satisfied as of the time of such breach or inaccuracy, but if such breach or inaccuracy is curable, then the Merger Agreement will not terminate pursuant to this provision as a result of a particular breach or inaccuracy until the expiration of a 30-day period after delivery of written notice of such breach or inaccuracy if such breach has not been cured; and (ii) PLx thereafter consummates a financing of at least $10.0 million or conducts a reorganization, consolidation, or merger of PLx pursuant to which the holders of PLxs securities prior to such transaction beneficially own less than 50% of the outstanding voting securities of the surviving entity after the transaction or the consummation of the sale, lease, transfer, conveyance or other disposition in one or a series of transactions, of all or substantially all of PLxs assets, or PLx and its subsidiaries, taken as a whole, to any person or entity.
CY2017Q1 us-gaap Loans Receivable Net
LoansReceivableNet
2000000 USD
CY2017Q1 us-gaap Lessee Leasing Arrangements Operating Leases Term Of Contract
LesseeLeasingArrangementsOperatingLeasesTermOfContract
P5Y5M
CY2017Q1 us-gaap Operating Leases Future Minimum Payments Due
OperatingLeasesFutureMinimumPaymentsDue
1280000 USD
CY2012Q2 us-gaap Loss Contingency Number Of Defendants
LossContingencyNumberOfDefendants
30 pure
CY2012Q2 dprx Loss Contingency Number Of Defendants Represented By Original Executives
LossContingencyNumberOfDefendantsRepresentedByOriginalExecutives
2 pure
CY2012Q2 dprx Loss Contingency Number Of Defendants Represented By Executives And Reporting Entity
LossContingencyNumberOfDefendantsRepresentedByExecutivesAndReportingEntity
3 pure
CY2017Q1 us-gaap Increase Decrease In Accrued Interest Receivable Net
IncreaseDecreaseInAccruedInterestReceivableNet
36822 USD
CY2017Q1 us-gaap Payments To Acquire Notes Receivable
PaymentsToAcquireNotesReceivable
2000000 USD
CY2016Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
0 USD
CY2017Q1 us-gaap Notes And Loans Receivable Net Noncurrent
NotesAndLoansReceivableNetNoncurrent
2000000 USD
CY2016Q4 us-gaap Notes And Loans Receivable Net Noncurrent
NotesAndLoansReceivableNetNoncurrent
0 USD
CY2016Q1 us-gaap Payments To Acquire Notes Receivable
PaymentsToAcquireNotesReceivable
0 USD

Files In Submission

Name View Source Status
0001144204-17-020705-index-headers.html Edgar Link pending
0001144204-17-020705-index.html Edgar Link pending
0001144204-17-020705.txt Edgar Link pending
0001144204-17-020705-xbrl.zip Edgar Link pending
dprx-20170331.xml Edgar Link completed
dprx-20170331.xsd Edgar Link pending
dprx-20170331_cal.xml Edgar Link unprocessable
dprx-20170331_def.xml Edgar Link unprocessable
dprx-20170331_lab.xml Edgar Link unprocessable
dprx-20170331_pre.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
v463352_10q.htm Edgar Link pending
v463352_ex31-1.htm Edgar Link pending
v463352_ex31-2.htm Edgar Link pending
v463352_ex32-1.htm Edgar Link pending
v463352_ex32-2.htm Edgar Link pending